GlassScriptPhysician profile
William M Tucker
NPI 1790861409
$7,246.12
in general payments reported to CMS, 2019-2025
44 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $954 · 2021: $880 · 2022: $1,168 · 2023: $1,304 · 2024: $1,249 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,164.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,059.36 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $743.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $701.12 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $675.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $605.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $602.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $332.99 | 2019-2025 | Jardiance, Synjardy |
| Allergan, INC. | $299.80 | 2019-2020 | |
| Amgen INC. | $245.97 | 2019-2025 | Repatha, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.12 | 2019-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $156.52 | 2023-2024 | Qelbree, Qelbree |
| Astellas Pharma US INC | $153.22 | 2019-2024 | Veozah |
| Boston Scientific Corporation | $148.81 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $146.34 | 2022 | |
| Merck Sharp & Dohme LLC | $97.94 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.